About Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is a company based in San Diego (United States) founded in 2006 was acquired by Pfizer in April 2021.. Amplyx Pharmaceuticals has raised $144.31 million across 19 funding rounds from investors including Pfizer, HHS and Arix Bioscience. The company has 15 employees as of December 31, 2015. Amplyx Pharmaceuticals operates in a competitive market with competitors including Scynexis, F2g, Biosergen, Elion Therapeutics and Mycovia Pharmaceuticals, among others.
- Headquarter San Diego, United States
- Employees 15 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amplyx Pharmaceuticals Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has successfully raised a total of $144.31M across 19 strategic funding rounds. The most recent funding activity was a Series C round of $91.33 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Series C — $91.3M
-
First Round
First Round
(22 Sep 2008)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series C - Amplyx Pharmaceuticals | Valuation | Sofinnova Investments | |
| Aug, 2017 | Amount | Grant - Amplyx Pharmaceuticals | Valuation |
investors |
|
| Jul, 2016 | Amount | Grant - Amplyx Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, HHS and Arix Bioscience. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Investments in biotech startups are made by Arix Bioscience.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amplyx Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Amplyx Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amplyx Pharmaceuticals Comparisons
Competitors of Amplyx Pharmaceuticals
Amplyx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Biosergen, Elion Therapeutics and Mycovia Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| domain | founded_year | HQ Location |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amplyx Pharmaceuticals
Frequently Asked Questions about Amplyx Pharmaceuticals
When was Amplyx Pharmaceuticals founded?
Amplyx Pharmaceuticals was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Where is Amplyx Pharmaceuticals located?
Amplyx Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Amplyx Pharmaceuticals?
Mike Grey is the current CEO of Amplyx Pharmaceuticals.
Is Amplyx Pharmaceuticals a funded company?
Amplyx Pharmaceuticals is a funded company, having raised a total of $144.31M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1.46M, raised on Sep 22, 2008.
How many employees does Amplyx Pharmaceuticals have?
As of Dec 31, 2015, the latest employee count at Amplyx Pharmaceuticals is 15.
What does Amplyx Pharmaceuticals do?
Amplyx Pharmaceuticals is US-based, clinical stage biopharma developing broad-spectrum small molecule fungal enzyme inhibitors. The companys lead compound, APX001 (completed Phase I trials) has shown broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus, as well as high potency against rare, difficult-to-treat molds. APX001 targets the GWT1 enzyme required for glycophosphatidylinositol (GPI) anchor biosynthesis- this cellular process is required for the anchoring of proteins to both the fungal cell wall and cell membrane and is specific to fungi (not humans). By targeting this, the drug leads to errors in the cell wall of the fungi and their death.
Who are the top competitors of Amplyx Pharmaceuticals?
Who are Amplyx Pharmaceuticals's investors?
Amplyx Pharmaceuticals has 15 investors. Key investors include Pfizer, HHS, Arix Bioscience, Sofinnova, and NEA.